Winston Dunn
Company: University of Kansas Medical Center
Job title: Professor
Seminars:
2:00 pm Roundtable Discussion: Navigating the Future of MASH Drug Development in the GLP-1 Era From Biopsy to Biomarker 2:00 pm
A Paradigm Shift in Trial Design – The recent FDA acceptance of a non-invasive biomarker as a surrogate endpoint is a pivotal moment for drug development, which is set to transform clinical trials by reducing patient burden, improving recruitment and retention, and accelerating the path to regulatory approval for new therapies The New Therapeutic Foundation…Read more
day: Conference Day 2
2:45 pm Leveraging Biomarkers for Efficient MASH Patient Stratification to Reduced Screen-Failures in Clinical Trials 2:45 pm
Reviewing simple biomarkers to pre-screen patients for liver directed therapy and clinical trials Using advanced biomarkers to screen-patients for clinical trials and reduce screen-fail rateRead more
day: Conference Day 1